Zhaoke Ophthalmology

Company Drug

Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study

Fineline Cube Oct 28, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...

Company Drug

Zhaoke Ophthalmology Completes Enrollment for Intrarosa Phase III Trial

Fineline Cube Oct 27, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...

Drug

Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study

Fineline Cube Aug 11, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Drug

Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China

Fineline Cube Aug 3, 2022

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD

Fineline Cube Jul 7, 2022

Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China